Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda sues Taiyo over product recalls

This article was originally published in Scrip

Executive Summary

Takedahas filed a lawsuit seeking ¥2.8 billion ($26.9 million) in damages from fellow Japanese firm Taiyo Pharmaceutical Industry in relation to the contract manufacture of an injectable antibiotic. Two lots of Pansporin (cefotiam) made by Taiyo were recalled last year following the discovery of glass fragments in two vials. In an action brought with the Osaka district court, Takeda said it was seeking the damages for insufficient quality control procedures and record keeping with regard to the identification of potentially defective products. Takeda noted that the suit followed the failure of direct negotiations with Taiyo and that all of its injectable antibiotics were now made at an in-house plant in Japan.

You may also be interested in...

Takeda Culls Shunned Ex-Shire Asset After EC Lifts Antimonopoly Concerns

Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.

Latecomer Alunbrig Faces Entrenched Rivals After US 1L Approval

First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.

Post-IPO Zentalis Plows New Ground With China Oncology Venture

US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio. 


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts